330 related articles for article (PubMed ID: 30468131)
1. Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets.
Fanunza E; Frau A; Corona A; Tramontano E
Infect Disord Drug Targets; 2019; 19(4):362-374. PubMed ID: 30468131
[TBL] [Abstract][Full Text] [Related]
2. Evasion of interferon responses by Ebola and Marburg viruses.
Basler CF; Amarasinghe GK
J Interferon Cytokine Res; 2009 Sep; 29(9):511-20. PubMed ID: 19694547
[TBL] [Abstract][Full Text] [Related]
3. Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.
Williams CG; Gibbons JS; Keiffer TR; Luthra P; Edwards MR; Basler CF
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295912
[TBL] [Abstract][Full Text] [Related]
4. Quercetin Blocks Ebola Virus Infection by Counteracting the VP24 Interferon-Inhibitory Function.
Fanunza E; Iampietro M; Distinto S; Corona A; Quartu M; Maccioni E; Horvat B; Tramontano E
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366711
[TBL] [Abstract][Full Text] [Related]
5. Lloviu virus VP24 and VP35 proteins function as innate immune antagonists in human and bat cells.
Feagins AR; Basler CF
Virology; 2015 Nov; 485():145-52. PubMed ID: 26255028
[TBL] [Abstract][Full Text] [Related]
6. Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production.
Corona A; Fanunza E; Salata C; Morwitzer MJ; Distinto S; Zinzula L; Sanna C; Frau A; Daino GL; Quartu M; Taglialatela-Scafati O; Rigano D; Reid S; Mirazimi A; Tramontano E
Antiviral Res; 2022 Feb; 198():105251. PubMed ID: 35066016
[TBL] [Abstract][Full Text] [Related]
7. The Host E3-Ubiquitin Ligase TRIM6 Ubiquitinates the Ebola Virus VP35 Protein and Promotes Virus Replication.
Bharaj P; Atkins C; Luthra P; Giraldo MI; Dawes BE; Miorin L; Johnson JR; Krogan NJ; Basler CF; Freiberg AN; Rajsbaum R
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679761
[TBL] [Abstract][Full Text] [Related]
8. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.
Ilinykh PA; Lubaki NM; Widen SG; Renn LA; Theisen TC; Rabin RL; Wood TG; Bukreyev A
J Virol; 2015 Aug; 89(15):7567-83. PubMed ID: 25972536
[TBL] [Abstract][Full Text] [Related]
9. Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.
Kuzmin IV; Schwarz TM; Ilinykh PA; Jordan I; Ksiazek TG; Sachidanandam R; Basler CF; Bukreyev A
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122983
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional Analysis of Lymphoid Tissues from Infected Nonhuman Primates Reveals the Basis for Attenuation and Immunogenicity of an Ebola Virus Encoding a Mutant VP35 Protein.
Pinski A; Woolsey C; Jankeel A; Cross R; Basler CF; Geisbert T; Messaoudi I
J Virol; 2021 Feb; 95(6):. PubMed ID: 33408171
[TBL] [Abstract][Full Text] [Related]
11. Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection.
Yen BC; Basler CF
J Virol; 2016 May; 90(10):5108-5118. PubMed ID: 26962215
[TBL] [Abstract][Full Text] [Related]
12. Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism.
Seesuay W; Jittavisutthikul S; Sae-Lim N; Sookrung N; Sakolvaree Y; Chaicumpa W
Emerg Microbes Infect; 2018 Mar; 7(1):41. PubMed ID: 29568066
[TBL] [Abstract][Full Text] [Related]
13. The Ebola virus VP35 protein binds viral immunostimulatory and host RNAs identified through deep sequencing.
Dilley KA; Voorhies AA; Luthra P; Puri V; Stockwell TB; Lorenzi H; Basler CF; Shabman RS
PLoS One; 2017; 12(6):e0178717. PubMed ID: 28636653
[TBL] [Abstract][Full Text] [Related]
14. The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.
Lubaki NM; Younan P; Santos RI; Meyer M; Iampietro M; Koup RA; Bukreyev A
PLoS Pathog; 2016 Dec; 12(12):e1006031. PubMed ID: 27930745
[TBL] [Abstract][Full Text] [Related]
15. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
Hartman AL; Dover JE; Towner JS; Nichol ST
J Virol; 2006 Jul; 80(13):6430-40. PubMed ID: 16775331
[TBL] [Abstract][Full Text] [Related]
16. VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability.
Schwarz TM; Edwards MR; Diederichs A; Alinger JB; Leung DW; Amarasinghe GK; Basler CF
J Virol; 2017 Feb; 91(4):. PubMed ID: 27974555
[TBL] [Abstract][Full Text] [Related]
17. Ebolavirus VP35 is a multifunctional virulence factor.
Leung DW; Prins KC; Basler CF; Amarasinghe GK
Virulence; 2010; 1(6):526-31. PubMed ID: 21178490
[TBL] [Abstract][Full Text] [Related]
18. A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.
Woolsey C; Menicucci AR; Cross RW; Luthra P; Agans KN; Borisevich V; Geisbert JB; Mire CE; Fenton KA; Jankeel A; Anand S; Ebihara H; Geisbert TW; Messaoudi I; Basler CF
Cell Rep; 2019 Sep; 28(12):3032-3046.e6. PubMed ID: 31533029
[TBL] [Abstract][Full Text] [Related]
19. Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication.
Cao Z; Liu C; Peng C; Ran Y; Yao Y; Xiao G; Li E; Chen Z; Chuai X; Chiu S
Virol Sin; 2023 Dec; 38(6):922-930. PubMed ID: 37839549
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the Ebola Virus VP24 Protein by SUMO.
Vidal S; El Motiam A; Seoane R; Preitakaite V; Bouzaher YH; Gómez-Medina S; San Martín C; Rodríguez D; Rejas MT; Baz-Martínez M; Barrio R; Sutherland JD; Rodríguez MS; Muñoz-Fontela C; Rivas C
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
